ASMB starts phase-2 for second-generation HBV CpAM, ABT-H2158: https://www.globenewswire.com/news-release/2020/06/25/2053349/0/en/Assembly-Biosciences-Initiates-Phase-2-Trial-Evaluating-Second-Generation-Core-Inhibitor-ABI-H2158-for-Chronic-Hepatitis-B-Infection.html ASMB’s first-generation CpAM, ABI-H0731, has shown only modest efficacy (#msg-152253534). ENTA’s EDP-514, in phase-2, is also a CpAM.